Fair Value Calculator Fair Value Calculator
EN DE

6669 (6669) Fair Value & Analysis

Healthcare · Market cap HK$2.4B

6 6669 6669 · HK
PriceHK$7.55
Fair ValueHK$8.84
Upside+17.1%
Quality59/100
Watch 6669 for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range HK$6.75 – HK$10.92

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −15.7% over the past month.

Price vs Fair Value (12 months)

HK$15.14 HK$7.55 Fair Value HK$8.84 Jun 2025 Jul 2026

12‑month range HK$7.55 – HK$15.14 · fair‑value band HK$6.75 – HK$10.92 · the HK$7.55 price screens below the HK$8.84 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6669 (6669) currently trades at HK$7.55, while our model-based Fair Value estimate is HK$8.84 — implying the stock looks roughly 17.1% undervalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 6669 generated revenue of HK$645M at a net margin of 18.5%. Revenue grew 21.4% year over year. It earns a return on equity of 8.4%. The balance sheet holds a net cash position of HK$156M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$645M
Revenue growth (YoY) +21.4%
Net margin 18.5%
Return on equity 8.4%
Free cash flow HK$145M FY2025
P/E ratio 16.8
More key figures
Operating margin 9.7%
EPS (TTM) HK$0.2900
EPS growth (YoY) +150%
Net cash HK$156M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6669 reported revenue of HK$645M in FY2025 versus HK$304M in FY2021, a compound +20.7%/yr. Reported net income was HK$119M in FY2025.

Revenue +20.7%/yr
FY21 HK$304M
FY22 HK$396M
FY23 HK$474M
FY24 HK$534M
FY25 HK$645M
Net income
FY21 −HK$79.1M
FY22 HK$70.1M
FY23 HK$14.5M
FY24 HK$52.3M
FY25 HK$119M

Is 6669 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
ABT ABT 1,600 MXN 1,231 MXN -23%
Abbott Laboratories, ABTT34 R$39.41 R$30.42 -23%
Stryker Corporation S1YK34 R$79.21 R$43.74 -45%
Medtronic plc MDT $81.67 $60.02 -27%
Boston Scientific Corporation B1SX34 R$229.30 R$43.33 -81%
Edwards Lifesciences Corporation EW $85.98 $41.02 -52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 6669 (6669) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$8.84 versus a price of HK$7.55 — about +17% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6669?
Our model-based fair value for 6669 is HK$8.84 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$7.55.
What is the quality score of 6669?
6669 has a Quality Score of 59/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 6669 (6669)?
6669 reported trailing-twelve-month revenue of about HK$645M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 6669?
The net profit margin of 6669 is about 18.5%, meaning it keeps roughly 18.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.